Technical analysis of Tenaya Therapeutics, Inc. (TNYA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Price Performance
| 1 month | -5.84% |
| 3 months | -9.98% |
| Year-to-date | -7.56% |
| 1 year | -46.09% |
| 3 years | -77.51% |
| 5 years | -96.85% |
52-Week Range
| 52-week High | $2.35 |
| 52-week Low | $0.53 |
| Avg Volume (90d) | 2.8M |
Technical Indicators
| SMA 50 | $0.74 |
| SMA 200 | $0.78 |
| Beta | 3.00 |
| 30-day Volatility (annualised) | 47.7% |
| Price vs SMA 50 | -11.1% |
| Price vs SMA 200 | -15.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.44 | |
| 2025-11 | $1.40 | -2.8% |
| 2025-12 | $0.71 | -49.2% |
| 2026-01 | $0.77 | +8.9% |
| 2026-02 | $0.56 | -27.5% |
| 2026-03 | $0.69 | +23.2% |
| 2026-04 | $0.69 | -0.2% |
| 2026-05 | $0.87 | +25.7% |
| 2026-06 | $0.74 | -14.9% |
| 2026-07 | $0.74 | +0.2% |
| 2026-08 | $0.69 | -7.1% |
| 2026-09 | $0.66 | -4.4% |
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.05 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.52 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -4.36 |